Recombinant Newcastle disease virus kills liver cancer in vitro and in vivo

Plain language summary What does this study talk about?This is a basic research article about Recombinant Newcastle disease virus. Given the excellent antitumor effect of IP10 protein and the good oncolytic effect of Newcastle disease virus, we expect to add the two effects to produce chemical action to kill tumor cells. What is the result of this study?We have done experiments in vivo and in vitro, which show that the antitumor effect is very good. Our research shows that the sum of the two results is greater than the single, which may provide new ideas for future clinical antitumor research. Aim: To construct and rescue a recombinant Newcastle disease virus that can express IP10 protein and evaluate its targeted killing effect on liver cancer in vivo and in vitro. Materials & methods: Fluorescence quantitative PCR, western blot and ELISA were used to detect the expression and secretion of IP10 in cells. The H22 mouse liver cancer cells were used to establish subcutaneous tumor-bearing mice experimental animal tumor models, and the tumor growth of mice in each group was observed while receiving treatment with rLasota. Results: The recombinant Newcastle disease virus was successfully constructed and can kill tumor cells successfully. Conclusion: The rLasota-IP10-IRES-EGFP achieves antitumor effects by killing hepatocellular carcinoma cells, enhancing T-lymphocyte infiltration in tumor tissues and inhibiting neovascularization. Tweetable abstractRecombinant Newcastle disease virus rLasota-IP10-IRES-EGFP has been constructed and rescued. The rLasota-IP10-IRES-EGFP achieves antitumor effects by killing hepatocellular carcinoma cells, enhancing T-lymphocyte infiltration in tumor tissues and inhibiting neovascularization.